These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 38906341

  • 1. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
    Johannesson M, Söderberg L, Zachrisson O, Fritz N, Kylefjord H, Gkanatsiou E, Button E, Svensson AS, Rachalski A, Nygren P, Osswald G, Lannfelt L, Möller C.
    Mol Cell Neurosci; 2024 Sep; 130():103949. PubMed ID: 38906341
    [Abstract] [Full Text] [Related]

  • 2. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.
    Rizoska B, Zachrisson O, Appelkvist P, Boström E, Björklund M, Rachalski A, Gkanatsiou E, Kylefjord H, Söderberg L, Nygren P, Eriksson F, Ishikawa Y, Fukushima T, Koyama A, Osswald G, Lannfelt L, Möller C.
    Mol Cell Neurosci; 2024 Sep; 130():103950. PubMed ID: 38901655
    [Abstract] [Full Text] [Related]

  • 3. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E, Sahlin C, Portelius E, Johannesson M, Söderberg L, Fälting J, Basun H, Möller C, Odergren T, Zetterberg H, Blennow K, Lannfelt L, Brinkmalm G.
    Neurosci Lett; 2021 May 29; 754():135894. PubMed ID: 33848613
    [Abstract] [Full Text] [Related]

  • 4. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.
    Colvin BA, Rogers VA, Kulas JA, Ridgway EA, Amtashar FS, Combs CK, Nichols MR.
    J Neurochem; 2017 Dec 29; 143(6):736-749. PubMed ID: 28881033
    [Abstract] [Full Text] [Related]

  • 5. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
    Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, Söderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L.
    J Alzheimers Dis; 2015 Dec 29; 43(2):575-88. PubMed ID: 25096615
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta.
    Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, Metzendorf NG, Gustavsson T, Sehlin D, Söderberg L, Hultqvist G.
    Transl Neurodegener; 2021 Sep 28; 10(1):38. PubMed ID: 34579778
    [Abstract] [Full Text] [Related]

  • 9. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.
    Am J Pathol; 1999 Sep 28; 155(3):853-62. PubMed ID: 10487842
    [Abstract] [Full Text] [Related]

  • 10. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L.
    Neurotherapeutics; 2023 Jan 28; 20(1):195-206. PubMed ID: 36253511
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.
    Miners JS, Clarke P, Love S.
    Brain Pathol; 2017 May 28; 27(3):305-313. PubMed ID: 27248362
    [Abstract] [Full Text] [Related]

  • 13. A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease.
    Chen ZL, Singh PK, Calvano M, Norris EH, Strickland S.
    Proc Natl Acad Sci U S A; 2023 Sep 05; 120(36):e2309389120. PubMed ID: 37639602
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures.
    Terrill-Usery SE, Colvin BA, Davenport RE, Nichols MR.
    Arch Biochem Biophys; 2016 May 01; 597():1-11. PubMed ID: 27013205
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains.
    Stern AM, Yang Y, Jin S, Yamashita K, Meunier AL, Liu W, Cai Y, Ericsson M, Liu L, Goedert M, Scheres SHW, Selkoe DJ.
    Neuron; 2023 Jul 05; 111(13):2012-2020.e4. PubMed ID: 37167969
    [Abstract] [Full Text] [Related]

  • 19. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients.
    Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B.
    Neurochem Int; 2009 Jul 05; 54(5-6):347-57. PubMed ID: 19162107
    [Abstract] [Full Text] [Related]

  • 20. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L.
    Alzheimers Res Ther; 2024 May 10; 16(1):105. PubMed ID: 38730496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.